Table S2. Descriptives of Fc N-glycosylation features and serum mediators among distinct clinical-epidemiological populations

	VL median (IQR)	ASYMP median (IQR)	EC median (IQR)	NC median (IQR)
IgG1 glyco features				
Gal	23.3 (18.0)	42.0 (12.7)***	43.5 (13.1)***	48.3 (8.94)***
Sial	1.7 (2.4)	3.9 (2.7)***	4.2 (2.5)***	4.8 (2.6)***
Sial/Gal	3.5 (2.6)	4.8 (2.2)***	4.7 (2.1)***	5.2 (2.1)***
BisGlcNAc	3.6 (3.6)	6.7 (3.3)***	7.0 (3.0)***	6.3 (3.1)***
Core Fuc	99.7 (0.9)	97.9 (2.8)***	98.2 (2.7)***	97.6 (2.7)***
IgG2&3 glyco features				
Gal	15.9 (12.1)	32.6 (12.3)***	34.4 (13.6)***	39.0 (6.7)***
Sial	1.3 (2.9)	4.0 (3.2)***	4.2 (2.7)***	5.0 (2.4)***
Sial/Gal	4.4 (6.5)	6.3 (3.1)***	5.9 (2.3)***	6.7 (2.3)***
BisGlcNAc	3.5 (4.3)	5.6 (2.7)***	5.6 (2.4)***	5.2 (2.1)*
Serum mediators				
IL-1β	1.9 (1.2)	1.4 (1.0)***	1.1 (0.8)**	-
IL-6	8.4 (29.9)	2.3 (1.9)***	1.8 (1.9)***	-
TNF-α	21.9 (44.9)	4.4 (7.4)***	1.3 (2.6)***	-
IL-12p70	5.4 (14.4)	4.3 (1.2)***	4.1 (1.6)**	-
IFN-γ	24.2 (74.5)	4.0 (3.7)***	4.2 (4.2)***	-
IL-17	4.6 (9.5)	2.7 (1.3)***	2.3 (2.3)***	-
IL-10	57.6 (174.1)	3.7 (3.3)***	3.3 (2.6)***	-
IL-5	1.9 (2.9)	1.3 (1.3)***	1.1 (1.2)**	-
IL-4	18.1 (24.8)	14.4 (9.0)	13.8 (6.1)	-
CRP	45.0 (55.5)	0.4 (1.2)***	0.1 (0.5)***	-

Abbreviations: IQR, interquartile range. Gal, level of galactosylation; Sial, level of sialylation; Bis GlcNAc, level of bisecting N-acetylglucosamine; Core F, level of core fucosylation,; IL, interleukin; TNF- α, tumor necrosis factor alfa; IFN-γ, interferon gamma; CRP, C-reactive protein. Statistically significant differences between (i) nonendemic controls, endemic controls and asymptomatic individuals and (ii) patients were evaluated by Kruskal-Wallis test and are given as *$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.001$.